UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 424, 2026

___________________________________

Oncolytics Biotech Inc.

(Exact name of registrant as specified in its charter)

___________________________________


Alberta, Canada (State or other jurisdiction of incorporation)	001-38512 (Commission File Number)		n/a (IRS Employer Identification No.)
4350 Executive Drive, Suite 325 San Diego, CA 92121		92121
(Address of principal executive offices)		(Zip Code)
(403) 670-7377
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common shares, no par value per share	ONCY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On February 424, 2026, Oncolytics Biotech, Inc. (the “Company”) issued a press release announcing ~~Fast~~it ~~Track~~will ~~Designation~~prioritize ~~from~~registrational ~~the~~or ~~U.S.~~registration-enabling ~~Food~~studies ~~And~~in ~~Drug~~colorectal ~~Administration~~and ~~for~~anal ~~the~~cancer. ~~combination~~The ofCompany ~~pelareorep,~~has ~~bevacizumab,~~also ~~leucovorin,~~concluded ~~fluorouracil,~~enrollment ~~irinotecan (FOLFIRI)~~ in ~~second-line~~the ~~KRAS-mutant~~GOBLET ~~microsatellite-stable~~gastrointestinal ~~metastatic~~cancer ~~colorectal caner~~study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

In addition to any of the Company’s filings with the U.S. Securities and Exchange Commission that automatically incorporate all filings made by the Company pursuant to Sections 13(a), 13(c), 14, and 15(d) of the U.S. Securities and Exchange Act of 1934, as amended, this Current Report on Form 8-K, including ~~Exhibit~~Exhibits 99.1 and 99.2 attached hereto, is hereby incorporated by reference as an exhibit to the Company’s Registration Statement on Form F-3 (File No. 333-289819).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release issued by Oncolytics Biotech, Inc., dated as of February 424, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 424, 2026


ONCOLYTICS BIOTECH, INC.

By:			/s/ Kirk Look
Name:			Kirk Look
Title:			Chief Financial Officer

Filing Compare · ONCOLYTICS BIOTECH INC